[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566948":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":44,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Beijing Boren Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T treatment","EXPERIMENTAL",null,[13],"Drug: CAR-T",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","CAR-T","CAR-T cells",[9],[21],{"name":22,"affiliation":23,"role":24},"Yajing Zhang, MD\u002FPhD","Beijing Gaobo Boren Hospital","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},"CONTACT","+8601083605002（716）","z18501333856@126.com",[31],{"facility":23,"status":11,"city":32,"state":11,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Beijing","100070","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100566948","a-study-of-car-t-cells-targeting-autoimmune-diseases-100566948",false,"NCT06661811","A Study of CAR-T Cells Targeting Autoimmune Diseases","A Study of CAR-T Cells Targeting B Cell Related Autoimmune Diseases","Inclusion Criteria:\n\n1. Male or female, between 18 and 56 years old;\n2. Diagnosed with Autoimmune Diseases；\n3. Good organ functions;\n4. Voluntary participates this trial and can comprehend and sign ICF.\n\nExclusion Criteria:\n\n1. Had or has active malignancy;\n2. Had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy;\n3. Combined with other autoimmune disease that needs treatment;\n4. Pregnant or lactating women;\n5. Has other factors that deemed not suitable by investigator.","ALL","18 Years","65 Years",{"count":57,"type":58},12,"ESTIMATED","INTERVENTIONAL",[61],"NA","The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.",[64],"Autoimmune Diseases","NOT_YET_RECRUITING","2024-10-25",{"date":68,"type":69},"2024-10-28","ACTUAL",{"date":71,"type":58},"2024-11-15",{"date":73,"type":58},"2028-06-20",{"name":5,"class":6},1]